Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

WCM/EADO 2021 | CMP-001 for melanoma and HNSCC

Art Krieg, MD, Checkmate Pharmaceuticals, Cambridge, MA, gives an overview of CMP-001, a virus-like particle which is a CpGA DNA toll-like receptor 9 agonist that can trigger a strong T-cell response. Intratumoral injection of CMP-001 can direct T-cells towards tumors. CMP-001 is currently being trialled in combination with pembrolizumab for patients with melanoma in the CMP-001-002 trial (NCT03084640), and in patients with head and neck squamous cell carcinoma (HNSCC) in the CMP-001-007 trial (NCT04633278). This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.

Disclosures

Art Krieg, MD, is the Founder and CSO of Checkmate Pharmaceuticals.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.